BNP Paribas Asset Management
SUPN icon

BNP Paribas Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

BNP Paribas Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.5K Sell
785
-137
-15% -$6.58K ﹤0.01% 1873
2026
Q1 		$47.7K Sell
922
-12,703
-93% -$647K ﹤0.01% 1764
2025
Q4 		$677K Buy
13,625
+13,188
+3,018% +$641K ﹤0.01% 1219
2025
Q3 		$21K Buy
437
+15
+4% +$604 ﹤0.01% 1375
2025
Q2 		$13K Buy
+422
New +$13.5K ﹤0.01% 1689

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

BNP Paribas Asset Management's SUPN Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Supernus Pharmaceuticals (SUPN) stake by 15% in Q2 2026, selling an estimated $6.58K and leaving 785 shares worth $36.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1873.

BNP Paribas Asset Management first reported a position in SUPN in Q2 2025 and has held it in 5 quarters since. The position peaked at $677K in Q4 2025. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • BNP Paribas Asset Management held 785 shares of Supernus Pharmaceuticals worth $36.5K as of Q2 2026.
  • BNP Paribas Asset Management sold 137 Supernus Pharmaceuticals shares in Q2 2026, an estimated $6.58K.
  • Supernus Pharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1873 holding.
  • BNP Paribas Asset Management first reported a position in Supernus Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Asset Management's Supernus Pharmaceuticals position peaked at $677K in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.